Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Cost effectiveness of antiretrovirals - long term or short term?

Flessa S.

Appl Health Econ Health Policy. 2009;7(4):225-7. doi: 10.2165/11314730-000000000-00000. No abstract available.

PMID:
19905036
2.

Is antiretroviral therapy cost-effective in South Africa?

Braithwaite RS, Tsevat J.

PLoS Med. 2006 Jan;3(1):e60. No abstract available.

3.

The cost of antiretroviral drugs and influence on prescribing policies.

Jones R, Gazzard B.

Int J STD AIDS. 2006 Aug;17(8):499-506. Review.

PMID:
16925892
4.

Providing antiretroviral therapy for HIV infection.

Steinbrook R.

N Engl J Med. 2001 Mar 15;344(11):844-6. No abstract available.

PMID:
11248164
5.
6.

Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.

Long EF, Brandeau ML, Galvin CM, Vinichenko T, Tole SP, Schwartz A, Sanders GD, Owens DK.

AIDS. 2006 Nov 14;20(17):2207-15.

PMID:
17086061
7.

Combining evidence for access to and benefits from antiretroviral treatment to inform planning.

Editorial Steering Committee., Marlink R, Forsythe S, Bertozzi SM, Muirhead D, Holmes M, Sturchio J.

AIDS. 2008 Jul;22 Suppl 1:S121-2. doi: 10.1097/01.aids.0000327632.08093.bd. No abstract available.

PMID:
18664943
8.

Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.

Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D.

J Acquir Immune Defic Syndr. 2001 May 1;27(1):14-9.

PMID:
11404515
9.

Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand.

Ono S, Kurotaki T, Nakasone T, Honda M, Boon-Long J, Sawanpanyalert P, Kimura K.

Jpn J Infect Dis. 2006 Jun;59(3):168-73.

10.

The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.

Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB, Lalonde R, Piché A, Hankins CA.

AIDS. 2004 Dec 3;18(18):2411-8.

PMID:
15622317
11.

Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.

Vijayaraghavan A, Efrusy MB, Mazonson PD, Ebrahim O, Sanne IM, Santas CC.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):91-100.

PMID:
17621241
12.

Assessing the cost-effectiveness of HAART for adults with HIV in England.

Miners AH, Sabin CA, Trueman P, Youle M, Mocroft A, Johnson M, Beck EJ.

HIV Med. 2001 Jan;2(1):52-8.

14.

HIV/AIDS, utilities, and cost-effectiveness analysis: stepping toward the future.

Holmes WC.

Med Decis Making. 2002 Nov-Dec;22(6):522-5. No abstract available.

PMID:
12458983
15.

Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.

Corzillius M, Mühlberger N, Sroczynski G, Jaeger H, Wasem J, Siebert U.

Antivir Ther. 2004 Feb;9(1):27-36.

PMID:
15040534
16.

Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.

Aracena-Genao B, Navarro JO, Lamadrid-Figueroa H, Forsythe S, Trejo-Valdivia B.

AIDS. 2008 Jul;22 Suppl 1:S141-8. doi: 10.1097/01.aids.0000327635.74919.fd.

PMID:
18664946
17.

Cost and cost-effectiveness of antiretroviral therapy for HIV infection in Singapore.

Paton NI, Chapman CA, Sangeetha S, Mandalia S, Bellamy R, Beck EJ.

Int J STD AIDS. 2006 Oct;17(10):699-705.

PMID:
17059641
18.

The economic viability of antiretroviral adherence interventions.

Bozzette SA, Gifford AL.

Am J Med. 2003 Dec 1;115(8):672-3. No abstract available.

PMID:
14656623
19.

Economic models of antiretroviral therapy: searching for the optimal strategy.

Hellinger FJ.

Pharmacoeconomics. 2006;24(7):631-42. Review.

PMID:
16802839
20.

The cost effectiveness of antiretroviral therapy for HIV disease.

Messori A, Trippoli S, Vaiani M.

N Engl J Med. 2001 Jul 5;345(1):68; author reply 68-9. No abstract available.

Items per page

Supplemental Content

Support Center